Bristol Myers Squibb Co (BMY) Net Income towards Common Stockholders (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Net Income towards Common Stockholders for 18 consecutive years, with $3.3 billion the latest figure, recorded in Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders rose 152.55% year-over-year to $3.3 billion; the TTM figure through Jun 2026 stood at $9.3 billion (up 83.1% YoY), while the FY2025 annual figure was $7.1 billion, up 178.99% from the prior year.
• Net Income towards Common Stockholders grew to $3.3 billion in Q2 2026 per BMY's latest filing, from $2.7 billion in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $3.3 billion in Q2 2026 and bottomed at -$11.9 billion in Q1 2024.
• Historically, Net Income towards Common Stockholders has averaged $1.0 billion across 5 years, with a median of $1.7 billion in 2023.
• Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders sank 625.28% — and 2025, when it soared 1328.95%.
• Bristol Myers Squibb's Net Income towards Common Stockholders stood at $2.0 billion in 2022, then declined by 12.99% to $1.8 billion in 2023, then slumped by 95.69% to $76.0 million in 2024, then jumped by 1328.95% to $1.1 billion in 2025, then surged by 205.34% to $3.3 billion in 2026.
• Business Quant data shows BMY's Net Income towards Common Stockholders at $3.3 billion in Q2 2026, $2.7 billion in Q1 2026, and $1.1 billion in Q4 2025.